Diana Valeria Pastrana

Diana Valeria Pastrana

Auto-generated profile, based on publicly available information

Diana Valeria Pastrana

National Cancer Institute

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Cell Host & Microbe
Verified
Journal Article
Closed access
RSRachel M. Schowalter
Rachel M. Schowalter
DPDiana V. Pastrana
Diana V. Pastrana
KPKatherine A. Pumphrey
Katherine A. Pumphrey
AMAdam L. Moyer
Adam L. Moyer
CBChristopher B. Buck
Christopher B. Buck

15 January 2004 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
CBChristopher B. Buck
Christopher B. Buck
DPDiana V. Pastrana
Diana V. Pastrana
DLDouglas R. Lowy
Douglas R. Lowy
JSJohn T. Schiller
John T. Schiller
Although the papillomavirus structural proteins, L1 and L2, can spontaneously coassemble to form virus-like particles, currently available methods for production of L1/L2 particles capable of transducing reporter plasmids into mammalian cells are technically demanding and relatively low-yield. In this report, we describe a simple 293 cell transfection method for efficient intracellular production of papillomaviral-based gene transfer vectors carrying reporter plasmids. Using bovine papillomavirus type 1 (BPV1) and human papillomavirus type 16 as model papillomaviruses, we have developed a system for producing papillomaviral vector stocks with titers of several billion transducing units per milliliter. Production of these vectors requires both L1 and L2, and transduction can be prevented by papillomavirus-neutralizing antibodies. The stocks can be purified by an iodixanol (OptiPrep) gradient centrifugation procedure that is substantially more effective than standard cesium chloride gradient purification. Although earlier data had suggested a potential role for the viral early protein E2, we found that E2 protein expression did not enhance the intracellular production of BPV1 vectors. It was also possible to encapsidate reporter plasmids devoid of BPV1 DNA sequences. BPV1 vector production efficiency was significantly influenced by the size of the target plasmid being packaged. Use of 6-kb target plasmids resulted in BPV1 vector yields that were higher than those with target plasmids closer to the native 7.9-kb size of papillomavirus genomes. The results suggest that the intracellular assembly of papillomavirus structural proteins around heterologous reporter plasmids is surprisingly promiscuous and may be driven primarily by a size discrimination mechanism.

1 April 2004 in Virology
Verified
Journal Article
Closed access
DPDiana V Pastrana
Diana V Pastrana
CBChristopher B. Buck
Christopher B. Buck
YPYuk-Ying S Pang
Yuk-Ying S Pang
CTCynthia D Thompson
Cynthia D Thompson
PCPhilip E Castle
Philip E Castle
JSJohn T Schiller
John T Schiller

14 July 2009 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
YTYanis L. Tolstov
Yanis L. Tolstov
DPDiana V. Pastrana
Diana V. Pastrana
HFHuichen Feng
Huichen Feng
JBJürgen C. Becker
Jürgen C. Becker
FJFrank J. Jenkins
Frank J. Jenkins
Patrick S. MoorePatrick S. Moore
Patrick S. Moore
Merkel cell polyomavirus (MCV) is a newly‐discovered human tumor virus found in ∼80% of Merkel cell carcinoma (MCC). The rate of MCV infection among persons without MCC is unknown. We developed a MCV virus‐like particle (VLP) enzyme‐linked immunoassay (EIA) that does not cross‐react with human BK or murine polyomaviruses. Peptide mapping of the MCV VP1 gene and immunoblotting with denatured MCV VLP are less sensitive than the MCV EIA in detecting MCV antibodies suggesting antibody reactivity in this assay primarily targets conformational but not linear epitopes. Among MCC patients, all 21 (100%) patients tested with MCV‐positive tumors had high serum MCV IgG but not high MCV IgM levels. Only 3 of 6 (50%) MCC patients with MCV‐negative tumors were positive for MCV antibodies. Sera from most adults, including 107 of 166 (64%) blood donors, 63 of 100 (63%) commercial donors and 37 of 50 (74%) systemic lupus erythematosus patients, show evidence for prior MCV exposure. Age‐specific MCV prevalence was determined by examining a cross‐sectional distribution of 150 Langerhans cell histiocytosis (an unrelated neoplasm) patient sera. MCV prevalence increases from 50% among children age 15 years or younger to 80% among persons older than 50 years. We did not find evidence for vertical transmission among infants. Although past exposure to MCV is common among all adult groups, MCC patients have a markedly elevated MCV IgG response compared with control patients. Our study demonstrates that MCV is a widespread but previously unrecognized human infection. © 2009 UICC

1 January 2005
Verified
Book Chapter
Closed access
PDF file
CBChristopher B. Buck
Christopher B. Buck
DPDiana V. Pastrana
Diana V. Pastrana
DLDouglas R. Lowy
Douglas R. Lowy
JSJohn T. Schiller
John T. Schiller

11 September 2009 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
DPDiana V Pastrana
Diana V Pastrana
YTYanis L Tolstov
Yanis L Tolstov
JBJürgen C Becker
Jürgen C Becker
Patrick S. MoorePatrick S. Moore
Patrick S. Moore
YCYuan Chang
Yuan Chang
CBChristopher B. Buck
Christopher B. Buck
Merkel cell carcinoma (MCC) is a relatively uncommon but highly lethal form of skin cancer. A majority of MCC tumors carry DNA sequences derived from a newly identified virus called Merkel cell polyomavirus (MCV or MCPyV), a candidate etiologic agent underlying the development of MCC. To further investigate the role of MCV infection in the development of MCC, we developed a reporter vector-based neutralization assay to quantitate MCV-specific serum antibody responses in human subjects. Our results showed that 21 MCC patients whose tumors harbored MCV DNA all displayed vigorous MCV-specific antibody responses. Although 88% (42/48) of adult subjects without MCC were MCV seropositive, the geometric mean titer of the control group was 59-fold lower than the MCC patient group (p<0.0001). Only 4% (2/48) of control subjects displayed neutralizing titers greater than the mean titer of the MCV-positive MCC patient population. MCC tumors were found not to express detectable amounts of MCV VP1 capsid protein, suggesting that the strong humoral responses observed in MCC patients were primed by an unusually immunogenic MCV infection, and not by viral antigen expressed by the MCC tumor itself. The occurrence of highly immunogenic MCV infection in MCC patients is unlikely to reflect a failure to control polyomavirus infections in general, as seroreactivity to BK polyomavirus was similar among MCC patients and control subjects. The results support the concept that MCV infection is a causative factor in the development of most cases of MCC. Although MCC tumorigenesis can evidently proceed in the face of effective MCV-specific antibody responses, a small pilot animal immunization study revealed that a candidate vaccine based on MCV virus-like particles (VLPs) elicits antibody responses that robustly neutralize MCV reporter vectors in vitro. This suggests that a VLP-based vaccine could be effective for preventing the initial establishment of MCV infection. For more than 50 years it has been known that some polyomavirus types can induce cancer in experimental animals. However, associations between the various polyomaviruses known to chronically infect most humans and the development of cancer have been difficult to uncover. Last year, DNA from a new human polyomavirus, called Merkel cell polyomavirus (MCV), was found embedded in an uncommon form of skin cancer called Merkel cell carcinoma. Emerging evidence indicates that most adults display detectable immune responses to MCV, suggesting that most individuals eventually become infected with the virus. In this study, we investigate antibodies that directly bind the protein coat of MCV, thereby obstructing its ability to penetrate cultured cells. We found that the magnitude of antibody responses against MCV varies dramatically among normal adults. Interestingly, patients suffering from MCV-associated Merkel cell carcinoma display uniformly strong antibody responses against the virus. This suggests that the development of Merkel cell carcinoma is preceded by an unusually robust MCV infection. It is currently unclear whether MCV infection may also be associated with additional diseases aside from Merkel cell carcinoma. Quantitation of immune responsiveness to the virus, using techniques reported here, could help identify such links.